Methylprednisolone
As of the edition of 20 October 2026, Methylprednisolone is a small molecule: marketed, first approved in 1959 (CH); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Medrol
- First approved
- 9 February 1959 (CH)
- Approvals on record
- 41 in 6 regions
- Holder of the most recent approval
- Pfizer; 4 holders in all
- Registered trials
- 529, 99 stopped early
- Disease areas
- Immune system; Blood and lymph; Cancer; Nervous system; Infections; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 74 | 34 | 9 | 11 |
| Phase 1 | 45 | 21 | 7 | 9 |
| Phase 2 | 190 | 90 | 39 | 41 |
| Phase 3 | 132 | 59 | 31 | 25 |
| Phase 4 | 88 | 41 | 12 | 13 |
| All trials | 529 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1959 to now |